FDA Advisers Unanimously Recommend Next Round Of COVID-19 Vaccines Target JN.1 Variant

The New York Times (6/5, Weiland, Jewett) reports, “A committee of advisers to the Food and Drug Administration voted on Wednesday to update the formula for the Covid vaccine ahead of an anticipated fall immunization campaign, now an annual step to try to offer better protection against versions of the virus in circulation.” The panel’s unanimous vote “recommends a formula aimed at combating the variant JN.1, which dominated infections in the United States in February, or a version of it.” CNN (6/5, Christensen) reports that if the FDA “agrees with its advisory committee, the new shot will be a monovalent vaccine, offering protection against one coronavirus variant. Some previous vaccines have been bivalent, meaning they were formulated to protect against two variants.”